ライフサイエンスコーパス: loss of heterozygosity

1 A mutation or high percentage of genome-wide loss of heterozygosity.

2 ied mutations with limited branching through loss of heterozygosity.

3 plasmic bacteria and results in an immediate loss of heterozygosity.

4 hromosomal defects and acquired copy-neutral loss of heterozygosity.

5 d as excessive sister chromatid exchange and loss of heterozygosity.

6 lances in chromosome number (aneuploidy) and loss of heterozygosity.

7 ion can expose deleterious mutations through loss of heterozygosity.

8 l lesion, indicating uniparental disomy with loss of heterozygosity.

9 s borderline tumor shared similar regions of loss of heterozygosity.

10 letion of wild-type alleles of both genes by loss of heterozygosity.

11 d with homozygous mutations in the region of loss of heterozygosity.

12 second hit at APC had arisen by copy-neutral loss of heterozygosity.

13 in Sufu+/-p53-/- animals resulted from Sufu loss of heterozygosity.

14 and with 1p and 16q copy number loss and/or loss of heterozygosity.

15 se because of haploinsufficiency rather than loss of heterozygosity.

16 potential for chromosomal rearrangements and loss of heterozygosity.

17 ed tumor and cell-free DNA samples revealing loss of heterozygosity.

18 thout evidence of other somatic mutations or loss of heterozygosity.

19 8p23.1, where human cancers frequently show loss of heterozygosity.

20 We also assessed APC gene loss of heterozygosity.

21 rossover-promoting repair pathways, prevents loss of heterozygosity.

22 enes by determining homozygous deletions and loss of heterozygosity.

23 tus was associated relapse (20% relapse with loss of heterozygosity, 25% with loss of imprinting, and

24 genotyping enables diagnosis of copy-neutral loss of heterozygosity, a lesion that cannot be detected

25 dromic and common form of fibroids; however, loss of heterozygosity across FH appeared as a significa

26 Loss of heterozygosity affecting chromosome 7q is common

27 The loss of heterozygosity/allelic imbalance at various mark

28 between clinicopathological features and the loss of heterozygosity/allelic imbalance in the stroma t

29 We found significant associations between loss of heterozygosity/allelic imbalance on chromosome 1

30 Association of the loss of heterozygosity/allelic imbalance, in both the st

31 ng for mutation hot spots and microsatellite loss of heterozygosity analysis.

32 mutation analysis and genomewide analysis of loss of heterozygosity and allelic imbalance on DNA from

33 We show that age-induced increases in loss of heterozygosity and chromosome loss events are co

34 Loss of heterozygosity and decreased copy number delimit

35 hat C/EBPalpha is down-regulated in HNSCC by loss of heterozygosity and DNA methylation, but not by g

36 tal cancers and cell lines, we find frequent loss of heterozygosity and mutations in BCL9L in aneuplo

37 of genetic stability in all species, with no loss of heterozygosity and no shifts in allele frequenci

38 in both families exhibited 9p deletion, with loss of heterozygosity and retention of the mutant PAX5

39 evel of global gene copy number alterations, loss of heterozygosity and single nucleotide variation (

40 segregation while limiting the potential for loss of heterozygosity and sister-chromatid exchanges.

41 was activation of the hedgehog pathway, with loss of heterozygosity and somatic mutation of the gene

42 xpression selects for inactivation of p53 by loss of heterozygosity and spontaneous and frequent inac

43 We analyzed 171 CLL cases for loss of heterozygosity and subchromosomal copy loss on c

44 tract gene conversion events associated with loss of heterozygosity and tandem duplications.

45 we show how TGCTs gain additional reciprocal loss of heterozygosity and that this is associated with

46 hances de novo tumor formation and precludes loss of heterozygosity and the PTEN locus.

47 o, and further characterize the link between loss of heterozygosity and the typical CALMs that appear

48 TEN) or have reduced PTEN expression through loss of heterozygosity and/or epigenetic silencing mecha

49 In this study, the loss of TIMP-3 by loss of heterozygosity and/or promoter hypermethylation

50 ele was homozygous after copy number-neutral loss-of-heterozygosity and amplified through a chromosom

51 velop lymphomas at higher incidence with p53 loss-of-heterozygosity and severe genome aneuploidy, sug

52 cies (BRCA mutant or BRCA wild-type and high loss of heterozygosity), and the intention-to-treat popu

53 e basis of evidence of activating mutations, loss of heterozygosity, and a mass forming proliferation

54 alterations encompassing somatic mutations, loss of heterozygosity, and aneuploidy.

55 dy might be protective against TALEN-induced loss of heterozygosity, and indeed Apc gene editing was

56 ifferent in each tumor (frameshift mutation, loss of heterozygosity, and methylation).

57 level, including promoter hypermethylation, loss of heterozygosity, and proteosomal degradation by n

58 tates; (ii) it can identify the copy-neutral loss of heterozygosity; and (iii) it is efficient in ter

59 Two types of acquired loss of heterozygosity are possible in cancer: deletions

60 ypermethylation of genes that also displayed loss of heterozygosity, as well as of genes that show co

61 t frequent somatic chromosome alteration was loss of heterozygosity at 16p (in 8 of 33 patients for w

62 The most frequent recurrent aberrations were loss of heterozygosity at 3p and 9p, observed in 39 (65%

63 be associated with favorable prognosis, and loss of heterozygosity at chromosome 6q (LOH6q) was repo

64 y, and volume; response to chemotherapy; and loss of heterozygosity at chromosomes 1p and 16q.

65 supertype (including HLA-B*15:01) or somatic loss of heterozygosity at HLA-I was associated with poor

66 ll set of chromosomes from each parent, with loss of heterozygosity at some loci, and uniparental ret

67 Of these, loss of heterozygosity at specific chromosomal sites sta

68 Furthermore, loss of heterozygosity at the Chr.16q24.3 locus in breas

69 to germline genotype misclassification from loss of heterozygosity at the CYP2D6 locus.

70 ute lymphoblastic lymphoma, we reported that loss of heterozygosity at the Fbxw7 locus occurs frequen

71 We found no loss of heterozygosity at the genomic level for the PTEN

72 ound of germline haploinsufficiency to cause loss of heterozygosity at the GNAS locus and lead to the

73 oteins were tested for the ability to induce loss of heterozygosity at the golden locus in zebrafish

74 ting mutations of PIK3CA (13.6%, n = 22) and loss of heterozygosity at the PTEN locus (25%, n = 8).

75 Preferential loss of heterozygosity at the rs1042522 locus of the tum

76 ry breast tumors revealed that 23% displayed loss of heterozygosity at the SPEN locus and that 3% to

77 well as adenocarcinoma of the colon, without loss of heterozygosity at the Tgfbr1 locus.

78 s of TbetaRIII expression is mediated by the loss of heterozygosity at the TGFBR3 genomic locus and e

79 fected tissue for genotyping; in such cases, loss of heterozygosity at the TP53 locus could lead to d

80 ional selective advantage resulting from the loss of heterozygosity at the TP53 locus.

81 Using microsatellite PCR to map loss-of-heterozygosity breakpoints within individual col

82 e lost their WT copy of the Apc gene through loss of heterozygosity by homologous somatic recombinati

83 ntributes to genomic instability, leading to loss of heterozygosity, chromosome rearrangements and ce

84 ng recurrent microdeletions and copy-neutral loss of heterozygosity (CN-LOH) in patients with diverse

85 urdens had evidence of acquired copy-neutral loss of heterozygosity (CN-LOH) of chromosome 1p in gran

86 In addition, three copy-neutral loss of heterozygosity (CN-LOH) regions greater than 1 M

87 ns (e.g., monosomy 7) or copy number neutral loss of heterozygosity (CN-LOH).

88 usly hidden chromosomal defect, copy neutral loss of heterozygosity (CN-LOH).

89 Subchromosomal copy number neutral loss of heterozygosity (CNN-LOH) can also be detected us

90 including TNFRSF14, but copy-number neutral loss of heterozygosity (CNN-LOH) of this locus was more

91 Remarkably, copy number-neutral loss of heterozygosity (CNN-LOH) on either 7q or 9p incl

92 Copy-number-neutral loss of heterozygosity (CNN-LOH) was identified at chrom

93 t of p53 mutations, or p53 mutations and 17p-loss of heterozygosity combined on survival in AML.

94 ing a missense mutation in one allele and a 'loss of heterozygosity' deletion encompassing the other.

95 In contrast, TP53 deletion and loss of heterozygosity did not confer worse survival.

96 Msh3/p53 tumors showed increased loss of heterozygosity, elevated genome-wide copy-number

97 ovide additional results for copy number and loss-of-heterozygosity estimation and assessing tumour p

98 ulent to Sr50 contained a 2.5 mega-base pair loss-of-heterozygosity event.

99 wed mutually exclusive endoreduplication and loss of heterozygosity events in clones present at diffe

100 ral abnormalities, defined as copy number or loss of heterozygosity events that are large and present

101 cinoma tumor sample; two of which are likely loss-of-heterozygosity events.

102 n Markov model to identify copy-neutral LOH (loss of heterozygosity) events as short as 11 Mb in mixt

103 ent with these observations, cells with TSC2 loss of heterozygosity expressed the OPG receptors, rece

104 e derived from a single parent, resulting in loss of heterozygosity for all single-nucleotide polymor

105 Loss of heterozygosity for BRCA1 was documented in these

106 anaplastic histology disease, recognition of loss of heterozygosity for chromosomes 1p and 16q as an

107 duals in family UW-AP exhibited copy-neutral loss of heterozygosity for large portions of the long ar

108 Moreover, loss of heterozygosity for the ATR locus was noted in or

109 re also found to have mutations in Cosmc and loss of heterozygosity for the cross-linked Cosmc locus.

110 alysis revealed no change in copy number but loss of heterozygosity for the entire length of chromoso

111 tumors collected from BALB/c-Trp53+/- mice, loss of heterozygosity for Trp53 was detected in more th

112 Loss of heterozygosity for TSC1 or TSC2 was found in 22%

113 ced migration of LAM cells identified by the loss of heterozygosity for TSC2.

114 was due to promoter hypermethylation and/or loss of heterozygosity, found in the majority of thyroid

115 This study therefore shows how loss of heterozygosity, hallmarked by VHL deletion in cc

116 ded as a nonneoplastic proliferation, albeit loss of heterozygosity has long been reported in a part

117 WT1 mutation and 11p15 loss of heterozygosity have been associated with relapse

118 WT1 mutation and 11p15 loss of heterozygosity have been associated with relapse

119 rs (mean homologous recombination deficiency-loss of heterozygosity/homologous recombination deficien

120 ous recombination deficiency was assessed by loss of heterozygosity (HRD-LOH) in pretreatment core br

121 tation of the remaining wild-type allele (or loss of heterozygosity), illustrating the strict correla

122 ressor gene that has been shown to undergo a loss of heterozygosity in 40-75% of human breast, ovaria

123 of Leu misincorporation resulted in complete loss of heterozygosity in a large region of chromosome V

124 hromosomal region frequently associated with loss of heterozygosity in a number of malignancies inclu

125 zed to chromosome 18q21, a frequent site for loss of heterozygosity in advanced stage colon cancers.

126 with NLS-RecA-Gal4 protein are able to cause loss of heterozygosity in approximately 3% of the inject

127 n reported to be associated with significant loss of heterozygosity in breast cancer.

128 coded in 16q24.3, a region in which there is loss of heterozygosity in breast, ovarian, hepatocellula

129 chromosome 11p15, which frequently undergoes loss of heterozygosity in esophageal adenocarcinoma (EAC

130 on 13q, and this region frequently displays loss of heterozygosity in human cancers.

131 Here, we present loss of heterozygosity in human leukocyte antigen (LOHHL

132 es from two patients but identified possible loss of heterozygosity in iPS cell lines from one patien

133 We found mutations with loss of heterozygosity in LZTR1, encoding an adaptor of

134 high-resolution method for modeling sporadic loss of heterozygosity in mice, providing insights into

135 this behavior is recapitulated by recurrent loss of heterozygosity in multiple metabolic genes adjac

136 es and may explain the high incidence of p53 loss of heterozygosity in mutant tumors.

137 mors were screened for somatic mutations and loss of heterozygosity in mutL homolog 1 (MLH1) and mutS

138 the left kidney, one from the right) showed loss of heterozygosity in one tumor, and four different

139 a higher degree of gene copy number loss and loss of heterozygosity in SNP array analyses.

140 ur results indicate that de novo mutation or loss of heterozygosity in stromal APC is sufficient to i

141 ans simultaneously deletes one copy of BAP1, loss of heterozygosity in the corresponding Vhl region i

142 , pancreatic, and parathyroid tumors showing loss of heterozygosity in the putative tumor suppressor

143 indicate that tumorigenesis necessitates NF1 loss of heterozygosity in the Schwann cell.

144 Despite this requisite NF1 loss of heterozygosity in the tumor cell of origin, nont

145 In particular, somatic mutations with loss of heterozygosity in TP53 were strongly associated

146 ressor encoded in 16q24.3 for which there is loss of heterozygosity in various solid tumors, is respo

147 r somatic, inherited, or de novo--as well as loss-of-heterozygosity in cancer cells.

148 ts with a germ line FAS mutation and somatic loss of heterozygosity, in whom biallelic mutant cells c

149 reveal that interplay between NHEJ and Trp53 loss of heterozygosity influences the sequence of multi-

150 deficiency, providing an explanation for why loss of heterozygosity is not required for the developme

151 ever, in the physiologic state, Schwann cell loss of heterozygosity is not sufficient for neurofibrom

152 CpG island methylator phenotype (CIMP); 18q loss of heterozygosity; KRAS, BRAF, and PIK3CA mutations

153 Thus, the oncological concept of somatic loss of heterozygosity leading to selected cell expansio

154 0.26, P = 0.002), and increased frequency of loss of heterozygosity (LOH) across the genome (median 9

155 For two of these genes, loss of heterozygosity (LOH) analysis of tSNPs in 314 ov

156 ssection followed by KRAS pyrosequencing and loss of heterozygosity (LOH) analysis on chromosomes 6q

157 A whole-genome loss of heterozygosity (LOH) analysis was performed usin

158 se are chromosomal segments characterized by loss of heterozygosity (LOH) and a normal copy number (t

159 A genome-wide screen for loss of heterozygosity (LOH) and chromosomal abnormaliti

160 BIR results in greatly increased spontaneous loss of heterozygosity (LOH) and chromosome mis-segregat

161 nterestingly, the distribution of long-range loss of heterozygosity (LOH) and chromosome rearrangemen

162 current areas of somatic copy number-neutral loss of heterozygosity (LOH) and deletions of chromosome

163 ERMS is associated with an 11p15.5 loss of heterozygosity (LOH) and may be confused with no

164 Recent studies have reported that frequent loss of heterozygosity (LOH) as well as allelic imbalanc

165 chromosome (chr) 8p with a common region of loss of heterozygosity (LOH) at chr8p22 locus.

166 Loss of heterozygosity (LOH) at chromosome 18q frequentl

167 atients with stage III FHWT without combined loss of heterozygosity (LOH) at chromosomes 1p and 16q t

168 ies to detect deletions, amplifications, and loss of heterozygosity (LOH) at high resolution.

169 ostic challenge by comparing the presence of loss of heterozygosity (LOH) at selected genetic locatio

170 The absence of loss of heterozygosity (LOH) at the Apc locus, combined

171 dly accelerate retinoblastoma, with frequent loss of heterozygosity (LOH) at the Arf locus.

172 umor phenotype is attenuated and altered and loss of heterozygosity (LOH) at the Trp53 wild-type locu

173 TOSE cells showed loss of heterozygosity (LOH) at TP53, increased nuclear

174 mmary epithelial cell model and show that 8p loss of heterozygosity (LOH) attenuates the action of se

175 H1 mutations, promoter hypermethylation, and loss of heterozygosity (LOH) by polymerase chain reactio

176 cordance between tumor and cell line for raw loss of heterozygosity (LOH) calls was 96% (range, 91-99

177 Loss of heterozygosity (LOH) can be a driving force in t

178 Nevertheless, loss of heterozygosity (LOH) for either Pdcd10 or Ccm2 r

179 formative sporadic cases of cHL, we detected loss of heterozygosity (LOH) for KLHDC8B in RS cells, bu

180 air events occur by gene conversion limiting loss of heterozygosity (LOH) for markers downstream of t

181 from ewsa(m/m);tp53(w/m) zebrafish displayed loss of heterozygosity (LOH) for the wildtype tp53 locus

182 ty to detect copy-number variation (CNV) and loss of heterozygosity (LOH) from exome sequencing data

183 By a genome-wide analysis of CNV and loss of heterozygosity (LOH) in 25 primary seminomas, we

184 sm arrays revealed copy number neutral (CNN) loss of heterozygosity (LOH) in 8% of patients.

185 s, we observed point mutations, deletions or loss of heterozygosity (LOH) in beta-2-microglobulin (B2

186 While studying loss of heterozygosity (LOH) in cancer tissues, we anecd

187 hoid system, we developed a method to induce loss of heterozygosity (LOH) in developing lymphocytes t

188 In this study, we observed loss of heterozygosity (LOH) in human chromosomal fragme

189 Men1(+/-); Cdk4(-/-) mice showed no signs of loss of heterozygosity (LOH) in the Men1 locus, whereas

190 e polymorphism (SNP) mapping arrays revealed loss of heterozygosity (LOH) involving 3 regions: the wh

191 Loss of heterozygosity (LOH) is one of the most importan

192 VLRWTs with low WT1 expression and/or 11p15 loss of heterozygosity (LOH) may have increased risk of

193 ith BRCA1 and BRCA2 (BRCA) mutations genomic loss of heterozygosity (LOH) might also represent homolo

194 Most cases (91%) show loss of heterozygosity (LOH) of chromosome 11p, with uni

195 he earliest events, followed by deletions or loss of heterozygosity (LOH) of chromosomes carrying TP5

196 Such recombination events often lead to loss of heterozygosity (LOH) of SNPs that are centromere

197 Loss of heterozygosity (LOH) of the hDMP1 locus was foun

198 revealed 95 deleted genes and 16 genes with loss of heterozygosity (LOH) on chromosome 3 in the diso

199 from p53+/- and p53-/- mice showed frequent loss of heterozygosity (LOH) on chromosome 6.

200 We previously mapped a nonrandom frequent loss of heterozygosity (LOH) region in cervical cancers

201 We examined DNA copy number alterations and loss of heterozygosity (LOH) to define the spectrum of m

202 from microdissected targets and analyzed for loss of heterozygosity (LOH) using a panel of 16 LOH mut

203 FABP7 expression loss in advanced melanomas, loss of heterozygosity (LOH) was assessed using microsat

204 cause cancers when the wild-type allele has loss of heterozygosity (LOH) within the cancer.

205 1 or BRCA2 allele (absence of locus-specific loss of heterozygosity (LOH)) is observed in 7% of BRCA1

206 Loss of heterozygosity (LOH), a causal event in cancer a

207 detailed information of copy number status, loss of heterozygosity (LOH), and event break points, wh

208 mal inversions, subtelomeric hypervariation, loss of heterozygosity (LOH), and whole or partial chrom

209 eled the chimeric tissue genotype of somatic loss of heterozygosity (LOH), by conditionally inactivat

210 determine copy number variations (CNVs) and loss of heterozygosity (LOH), comparing 138 cfDNA sample

211 squamous cell carcinoma (ESCC), we examined loss of heterozygosity (LOH), copy number (CN) loss, CN

212 use chromosomal rearrangements and extensive loss of heterozygosity (LOH), hallmarks of cancer cells.

213 oncocytoma, and clear cell with concomitant loss of heterozygosity (LOH), supporting a tumor suppres

214 ks by homologous recombination (HR) leads to loss of heterozygosity (LOH).

215 s by homologous recombination often leads to loss of heterozygosity (LOH).

216 llustrated by genetic alterations leading to loss of heterozygosity (LOH).

217 revealed an overall rate of 65% (80 of 124) loss of heterozygosity (LOH).

218 s are made of equal parental copy number and loss of heterozygosity (LOH).

219 ction with either a second point mutation or loss of heterozygosity (LOH).

220 Some of these mutations result in a loss of heterozygosity (LOH).

221 his syndrome detected four shared regions of loss of heterozygosity (LOH).

222 m individual alleles, allowing estimation of loss-of-heterozygosity (LOH) and allelic ratios to enhan

223 nd imbalanced losses and gains, copy-neutral loss-of-heterozygosity (LOH) and tetraploidy.

224 es, we studied the frequency and location of loss-of-heterozygosity (LOH) events on chromosome III in

225 Many cancers are initiated by loss-of-heterozygosity (LOH) events that lead to the rep

226 morphisms (SNPs), copy-number variations and loss-of-heterozygosity (LOH) events.

227 NP array data for inferring copy numbers and loss-of-heterozygosity (LOH) from paired normal and tumo

228 Identifying regions of loss-of-heterozygosity (LOH) in a tumor sample is a chal

229 brain-tissue-specific, large copy-number or loss-of-heterozygosity (LOH) variants involving multiple

230 ozygous/heterozygous deletions, copy-neutral loss-of-heterozygosity (LOH), allele-specific gains/ampl

231 mutations in one TP53 allele are followed by loss-of-heterozygosity (LOH), so tumors express only mut

232 any strains exhibit large genomic regions of loss-of-heterozygosity (LOH), suggesting that mitotic re

233 Completion of HR in G1 cells can lead to the loss-of-heterozygosity (LOH), which is potentially carci

234 different number of copies and copy-neutral loss-of-heterozygosity (LOH).

235 atus, and tumor location), molecular (1p/19q loss of heterozygosity [LOH], IDH1 mutation, and MGMT me

236 ice, intestinal adenomas showed copy-neutral loss of heterozygosity, making them homozygous for the m

237 us polyposis coli (APC), p53, K-RAS, and 17p loss of heterozygosity mutation burden was established u

238 l gains and losses, and several copy neutral loss-of-heterozygosity mutations at a genome-wide level,

239 et of OSCC patient samples in the absence of loss of heterozygosity, mutations, and promoter methylat

240 s of which, due to chromosomal deletions and loss of heterozygosity, necessitate the development of i

241 ed that a high percentage of genomic loss or loss of heterozygosity occurs at this locus in breast ca

242 Significant, tumour-specific loss of heterozygosity occurs in nine genes (ATM, BAP1,

243 WTs that show loss of heterozygosity of 11p15 or loss of imprinting of

244 d high-density SNP-A karyotyping to identify loss of heterozygosity of 11q in 442 patients with MDS,

245 urrent clinical trials have incorporated the loss of heterozygosity of 1p and 16q along with age, tum

246 17q11, 14q32 amplification, and copy-neutral loss of heterozygosity of 9p were gained in the B-LBL ce

247 sitional cell carcinomas of the bladder show loss of heterozygosity of a region spanning the TSC1 loc

248 e broadly applied to induce sporadic in vivo loss of heterozygosity of any conditional alleles in pro

249 Loss of heterozygosity of Apc and expression of cytokine

250 Apcmin/+/Sigirr-/- mice had increased loss of heterozygosity of Apc and microadenoma formation

251 Subsequent loss of heterozygosity of Dpc4 restores metastatic compe

252 tem, we examined our hypothesis by mimicking loss of heterozygosity of GNAS expression using dominant

253 However, loss of heterozygosity of Plk4 in mouse embryonic fibrob

254 Among those with SHH-MB, loss of heterozygosity of PTCH1 was associated with prol

255 cell culture model of cervical cancer, where loss of heterozygosity of the CDYL locus occurs.

256 egard to whether osteochondroma results from loss of heterozygosity of the Ext genes.

257 Loss of heterozygosity of the TRIM3 locus in approximate

258 Mutation was associated with loss of heterozygosity of the wild-type allele.

259 There was also a progressive loss of heterozygosity of the wild-type Apc allele in ad

260 cancer cells, which were identified by their loss of heterozygosity of Trp53 gene.

261 nduced selective migration of cells, showing loss of heterozygosity of TSC2 from a heterogeneous popu

262 tivation of KRAS and PIK3CA and mutation and loss of heterozygosity of tumor suppressor genes, such a

263 that further affect oncogenic signaling and loss of heterozygosity of tumor-suppressor genes.

264 rmalities, either aneuploidy or copy-neutral loss of heterozygosity, of >2 Mb in size in autosomes of

265 ertant clones of normal skin that arise from loss of heterozygosity on chromosome 17q via mitotic rec

266 was maintained in the tumors indicating that loss of heterozygosity on chromosome 9 is not driven by

267 Oligodendrogliomas with loss of heterozygosity on chromosomes 1p and 19q have a

268 reated oligodendroglioma, WHO grade II, with loss of heterozygosity on chromosomes 1p and 19q, which

269 To determine compartment-specific loci of loss of heterozygosity or allelic imbalance (LOH/AI) and

270 Stroma-specific loss of heterozygosity or allelic imbalance is associate

271 ster templates has the potential to generate loss of heterozygosity or genome rearrangements.

272 including inactivating mutations in WT1 and loss of heterozygosity or loss of imprinting at 11p15, w

273 Loss of PCDH8 expression is associated with loss of heterozygosity, partial promoter methylation, an

274 justed for performance status score, age, 1p loss of heterozygosity, presence of oligodendroglial ele

275 l carcinoma (OSCC) samples in the absence of loss-of-heterozygosity, promoter methylation, and mutati

276 ariations, mapped copy-number variations and loss of heterozygosity regions, and phased variants acro

277 Hierarchical cluster analysis of genome-wide loss of heterozygosity reveals that the incidence of EMT

278 Using SNP-A, we identified chromosome 7q loss of heterozygosity segments in 161 of 1458 patients

279 functionally inactivated in human cancer by loss of heterozygosity, somatic mutation, decreased expr

280 constrained by the inbreeding-like effect of loss of heterozygosity that accrues as gene conversion a

281 omatic mutation in a MMR gene, with possible loss of heterozygosity that could lead to MMR deficiency

282 c expression or loss, somatic mutagenesis or loss-of-heterozygosity (the first three also in a tumor-

283 various chromosomal instabilities, including loss of heterozygosity, translocations, and alternative

284 st to the cell, as BIR promotes mutagenesis, loss of heterozygosity, translocations, and copy number

285 clonal abnormalities including copy-neutral loss of heterozygosity (UPD, 7%).

286 for acquired genomic copy number changes and loss of heterozygosity using Affymetrix SNP 6.0 arrays,

287 Dict also detects differences in somatic and loss of heterozygosity variants between paired samples.

288 cations and reciprocal deletions (reciprocal loss of heterozygosity), variations that are significant

289 Loss of heterozygosity was associated with the onset of

290 Evidence for loss of heterozygosity was found in 100 and 76% of cases

291 The rate of loss of heterozygosity was higher (6%) for those with po

292 Genome-wide detection of loss of heterozygosity was performed using the Affymetri

293 Copy-neutral loss-of-heterozygosity was detected in 6% of CLL patient

294 c recombination events resulting in extended loss of heterozygosity were not observed in DS iPSCs.

295 Recurrent regions of copy-neutral loss-of-heterozygosity were identified at 1p (1%), 4q (0

296 otype AD) such aneuploidies have resulted in loss of heterozygosity, where a chromosomal region is re

297 el in any organism and show large regions of loss of heterozygosity, which we hypothesise to be a sho

298 ation or a germline FAS mutation and somatic loss-of-heterozygosity, which allows comparing the fate

299 Loss of heterozygosity with retention of an LZTR1 mutati

300 ormation-somatic copy number alterations and loss of heterozygosity-within a unified probabilistic fr